Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.
Adquey adds another nonsteroidal topical option for mild-to-moderate atopic dermatitis. Its approval is especially notable for how FDA evaluated two positive Japanese pivotal trials, supportive multinational evidence, and an incomplete U.S. Phase 3 study.
The first FDA approval confirms that a heterobifunctional degrader can complete the clinical and regulatory pathway. The broader pipeline and its growing record of discontinuations show why target degradation alone is not enough.
Single-trial approvals were already a substantial part of FDA practice before the 2026 policy debate. The revised draft guidance points toward wider use of one-trial programs, but not toward a lower evidentiary burden in every setting.
The lessons from failed Alzheimer's programs become clearer when read against the therapies that secured FDA approval. The resulting record shows that regulatory success depends on the complete alignment of mechanism, disease stage, exposure, biomarker strategy, clinical outcomes, safety, and approval pathway.
A research brief on how HIV treatment, long-acting prevention, and NRTI geroscience are converging around the broader question of healthspan.
Newly branded hypertension therapies are moving the category beyond traditional add-on sequencing. Baxfendy, Tryvio, lorundrostat, and zilebesiran illustrate an emerging split between approved oral options, pending class competition, and longer-horizon outcome-driven development.
Hyperlipidemia care in 2026 is moving from a statin-centered sequence toward earlier combination therapy, injectable and RNA-based options, and risk-stratified treatment of LDL-C, triglycerides, familial syndromes, and Lp(a). The future pipeline is broad, but most late-stage innovation still depends on outcomes data and label-specific regulatory interpretation.
Longevity medicine is increasingly built around repurposed metabolic, immunologic, and senolytic interventions, but no drug is approved to treat aging itself. The evidence base remains strongest for disease-risk modification and preclinical lifespan signals, not for demonstrated human lifespan extension.
IL-4 and IL-13-targeted therapy has evolved into a broader, more structurally complex market than it was just a few years ago. The field remains concentrated around dupilumab, while selective IL-13 antibodies and a China-based IL-4Rα entrant are building narrower but increasingly important positions.
CD38 has become one of the most commercially important plasma-cell targets in oncology, with daratumumab defining the category, isatuximab expanding into earlier myeloma settings, and a new wave of biosimilar and immune-mediated disease programs reshaping the next phase.
PD-1 and PD-L1 checkpoint inhibitors have become a mature oncology class dominated by a small number of high-value franchises, with commercial scale now best understood through annual manufacturer net sales, partial-period run-rate context, label breadth, subcutaneous lifecycle management, and earlier-stage disease expansion.
IL-11 blockade is a new frontier in anti-fibrotic therapy. This report reviews clinical progress, approvals, and future directions for IL-11-targeted drugs.
A research brief on therapeutic aging science, with emphasis on OSK partial reprogramming, first-in-human development, and the broader translational gap between longevity biology and approvable medical products.